Glenmark Pharmaceuticals Limited is a global pharmaceutical company headquartered in Mumbai, India. Established in 1977, the company has grown to become a leading player in the pharmaceutical industry, with a presence in over 80 countries worldwide. Glenmark focuses on developing and manufacturing innovative and affordable pharmaceutical products across various therapeutic areas, including dermatology, respiratory, cardiovascular, oncology, and more. The company’s research and development efforts are directed towards discovering and developing novel drugs and formulations to address unmet medical needs.
- Glenmark Pharmaceuticals Limited reported Total Income for Q4 FY23 of ₹3,333.50 Crore up from ₹3,126.34 Crore year on year, a growth of 6.6%.
- Total Expenses for Q4 FY23 of ₹3,024.53 Crore up from ₹2,774.12 Crore year on year, a growth of 9%.
- Consolidated Net Loss of ₹403.13 Crore, down from profit of ₹172.56 Crore in the same quarter of the previous year.
- The Earnings per Share is -₹15.18, up from ₹5.51 in the same quarter of the previous year.